Advarra Expands Gene Therapy Network to 1,500 Sites
Advarra's Gene Therapy Ready (GTR) global site network has reached a remarkable milestone of 1,500 sites. This extensive expansion aims to accelerate and enhance support for the growing number of investigational new drugs related to cell and gene therapy (CGT). By leveraging a robust evaluation process, Advarra has ensured that more CGT-ready sites are now available than any other institutional biosafety committee (IBC) review providers, establishing itself as the largest CGT site network in the clinical research field.
Supporting the Growth of CGT Trials
The surge in CGT innovation has been unprecedented, doubling the number of CGT investigational new drug (IND) applications since recent years. Currently, over 1,000 CGTs are in clinical development across the U.S., with thousands more in pre-clinical research. Advarra's expanded site network plays a critical role in supporting these complex therapies, thereby addressing the vital need for research infrastructure that complies with safety regulations.
Why Choose Advarra GTR Sites?
Institutions conducting gene therapy research must adhere to strict guidelines established by organizations such as the National Institutes of Health (NIH). Advarra is at the forefront, offering NIH-compliant oversight for CGT trials worldwide, thus ensuring both participant and staff safety. It connects sponsors and contract research organizations (CROs) more effectively to streamline initiation of trials, minimizing startup delays significantly.
Enhancing Research Capabilities
Advarra's infrastructure not only facilitates faster activation of trials but also significantly reduces the complexity associated with the procedural requirements of genetic material studies. With the GTR network’s expansive resources, sponsors can expect to initiate studies much quicker compared to the traditional route. The efficiency of this network helps overcome research hurdles, which can be particularly significant for innovative therapies.
Benefits for Diverse Research Landscapes
The broad geographic reach of Advarra's network means that they effectively support trials across various regions, ensuring that patients who typically lack access to cutting-edge therapies can benefit from participation in clinical studies. Advarra acknowledges this necessity and works diligently to increase patient accessibility, particularly for populations in rural areas.
Addressing the Challenges in CGT
While cell and gene therapies hold monumental potential in treating rare diseases and cancers, they also pose unique challenges. These challenges include regulatory complexities, ethical issues, logistical difficulties, and cost management. Advarra’s GTR sites are equipped to navigate these hurdles effectively, fostering innovation and progress in clinical research.
Success Stories from the Network
Clinical research executives from various organizations have hailed the advantages of using GTR sites, noting the impressive capabilities demonstrated during trial setups. For example, streamlined site activation and fast-track reviews have significantly boosted the confidence of sponsors in their ability to conduct complex clinical trials.
Building a Future for Patients
Ultimately, the expansion of Advarra's network signifies not just growth in scientific capabilities but also a crucial step forward in patient care. The creation of a vast network of 1,500+ locations allows Advarra to provide critical treatments and trials to individuals who may not otherwise have access. This initiative is a testament to Advarra’s commitment to innovation and patient-centric research.
Frequently Asked Questions
What is the Advarra Gene Therapy Ready Network?
The Advarra GTR network is comprised of 1,500 vetted research sites prepared to conduct complex cell and gene therapy clinical trials.
Why is the expansion of the GTR network important?
This expansion supports the growing demand for CGT treatments and ensures that patients have access to innovative therapies across diverse geographies.
How does Advarra ensure safety in clinical trials?
Advarra implements NIH-compliant oversight and thorough vetting of its research sites to prioritize the safety of all trial participants.
What advantages do sponsors gain from Advarra's GTR sites?
Sponsors reduce trial startup delays significantly and benefit from increased confidence thanks to the streamlined processes and specialized capabilities of Advarra's sites.
How does Advarra contribute to patient access to clinical trials?
By expanding its site network, Advarra increases patient access to clinical trials, especially in underserved and rural areas where treatment options may be limited.
